What is Cullinan Therapeutics, Inc.'s financing cash flow?

Cullinan Therapeutics, Inc. (CGEM) reported financing cash flow of $380K in Q1 2026.

What is the long-term trend for Cullinan Therapeutics, Inc.'s financing cash flow?

Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s financing cash flow has grown at a -74.8% compound annual growth rate (CAGR), from $268.78M to $1.09M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Cullinan Therapeutics, Inc. CGEM Financing Cash Flow

Financing Cash Flow at other companies

Eli LillyLLY

-$3.47B-351%

Johnson & JohnsonJNJ

$530M-94.9%

AmgenAMGN

$1.44B+135%

Regeneron PharmaceuticalsREGN

-$802.2M+26.3%

Janux TherapeuticsJANX

$3.55M+540%

Nektar TherapeuticsNKTR

$529.55M+7,564,886%

Other financials

Income statement

See full

Revenue-—

Operating income-$53.7M+2.4%

Net income-$49.7M-2.4%

EPS (diluted)-$0.69+24.2%

Balance sheet

See full

Cash & equivalents$75.1M-2.1%

Total debt$2.4M+29.5%

Total equity$408.7M-30.8%

Total assets$403.0M-30.5%

Cash flow

See full

Operating cash flow-$46.0M-6.7%

CapEx$11.0K—

Free cash flow-$38.1M-4.1%

Valuation

See full

Market cap$1.08B+140%

Enterprise value$1.01B+168%

Profitability

See full

Operating margin-358.7%—

Net margin-346.1%—

Returns & leverage

See full

Return on equity-44%+26.2pp

Debt / equity0×0.0×

Current ratio10.3×-1.3×

Where this comes from

Reported directly by Cullinan Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cullinan Therapeutics, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cullinan Therapeutics, Inc.'s financing cash flow?: Cullinan Therapeutics, Inc. (CGEM) reported financing cash flow of $380K in Q1 2026.
What is the long-term trend for Cullinan Therapeutics, Inc.'s financing cash flow?: Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s financing cash flow has grown at a -74.8% compound annual growth rate (CAGR), from $268.78M to $1.09M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.